Floatz logo

Recombinant Human Hyaluronidase

HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

National Cancer Institute (NCI)Phase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2/3B
Inno-206
National Cancer Institute (NCI)
Phase 2/3B
Azacitidine
National Cancer Institute (NCI)
Phase 2/3B
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3B
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 2/3B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2/3B
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD ANTIGEN CD27) (HUMAN MONOCLONAL CDX-1127 CLONE 1F5 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CDX-1127 CLONE 1F5 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2CC

Same molecule, other indications

Recombinant Human Hyaluronidase is also rated in:

follicular lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
Richter transformationDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →